Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2022 Earnings Presentation
16 slides from Indivior Pharmaceuticals's earnings presentation, Apr 28, 2022
Slide 1: Indivior PLC Q1 2022 Results
Indivior PLC Q1 2022 Results April 28, 2022
Slide 2: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 3: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 4: Q1 2022 key messages
Q1 2022 key messages Good start to the year; SUBLOCADE® drives top- and bottom-line growth Reconfirming FY 2022 guidance Returning value to shareholders with new $100m buyback; Consultations on additional US listing underway 4
Slide 5: Strategic Priorities report card: Q1 2022
Strategic Priorities report card: Q1 2022 Grow SUBLOCADE® Diversify Build Our Optimize >$1 bil. Revenue Pipeline Operating Model Q1 22 NR: $85m PERSERIS® Q1 22 NR: $5m SUBLOCADE®: Adj. Operating Profit**: +13% vs. Q4 21 unch. vs. Q4 21; +67% vs. Q1 Publication of buprenorphine- $54m fentanyl interac
Slide 6: Additional US listing – formal shareholder consultations proceeding
Additional US listing – formal shareholder consultations proceeding Spring / Summer July September Spring 2022 2022 2022 2023 Shareholder Board decision whether Early September: Implementation and consultations to proceed with formal EGM circular published commencement of shareholder vote additional
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Q1 2022 financial highlights
Q1 2022 financial highlights* Takeaways Profit & Loss ($ in mil. actual F/X) Q1 22 Q1 21 Change ➤ Double-digit top-line growth US Net Revenue $165 $131 26% ROW Net Revenue $42 $49 -14% ➤ SUBLOCADE NR up 98% YOY Total Net Revenue $207 $180 15% Key product NR ➤ Maintained strong financial SUBLOCADE NR
Slide 9: Cash & Borrowing position
Cash & Borrowing position Cash & Borrowing table Takeaways Total net cash & investments of $776m: ➤ Timing differences for government rebates ($ in mil.) Q1 22 FY 21 ➤ Annual settlement payments for DOJ and RB in Q1 ➤ Cash optimization strategy with portion of cash Cash & Cash Equivalents $874 $1,10
Slide 10: FY 2022 guidance unchanged
FY 2022 guidance unchanged Additional top-line items ➤ Underlying BMAT market growth of mid- to high-single digits ➤ SUBOXONE® Film • Assumes share erosion continues to diverge from analogs; FY 22 Guidance1 ($ in mil.) anticipate similar erosion rate to 2021 (just over 1pp) 2 • Traction for new prod
Slide 11: SUBOXONE Film indication and safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND USAGE SUBOXONE® Film is indicated for treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support HIGHLIGHTED SAFETY INFORMATION Prescr
Slide 12: SUBLOCADE indication and safety information
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment f
Slide 13: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 14: Appendix
Appendix So INDIVIOR
Slide 15: Income statement: Q1 2022 vs. Q1 2021
Income statement: Q1 2022 vs. Q1 2021 Q1 2022 Q1 2021 Δ Q1 2022 Q1 2022 Y-o-Y Q1 2021 Q1 2021 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 207 207 180 180 Cost of Sales (37) (37) (32) (32) Gross Profit 170 170 148 148 Gross Margin (%
Slide 16: Thank you
“AS INDIVIOR